Louvain-la-Neuve, Belgium– March 20, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announced it has signed a contract with Telix Pharmaceuticals Limited (Telix; ASX: TLX, NASDAQ: TLX), a precision oncology company, for the initial order of four Cyclone® KIUBE cyclotrons at standard IBA conditions[1]. The systems will be installed at select RLS Radiopharmacies (RLS) sites in the United States (U.S.).

This investment supports Telix’s strategic expansion of its U.S. manufacturing footprint with the goal of strengthening supply chain resilience and to enable in-house production of critical therapeutic and diagnostic isotopes and radiopharmaceuticals for cancer care. The agreement also contributes to the growth of IBA RadioPharma Solutions, reinforcing its leading position in the market. By combining IBA’s cyclotron expertise with Telix’s distribution and production footprint, this collaboration strengthens the collective capacity to meet the rising demand for sophisticated PET imaging tracers and other integrated theranostic solutions.

Telix selected the Cyclone® KIUBE 180 for its high-current capacity, industrial reliability, and capacity for future upgrades. Each cyclotron will be equipped with QUANTM® Irradiation System (QIS®), the latest irradiation system developed by ARTMS, a wholly-owned subsidiary of Telix Pharmaceuticals. Together, these technologies will enable cGMP-compliant production of critical radio-metals including Gallium-68 (68Ga), Zirconium-89 (89Zr), Technetium‐99m (99mTc) and Copper-64 (64Cu) initially. The integration of this advanced targetry hardware represents a key technical milestone, enabling efficient, high-yield, localized production of high-demand isotopes, reducing reliance on external suppliers and mitigating supply chain risk.
Charles Kumps, President of IBA RadioPharma Solutions, commented:
“We are proud to deepen our partnership with Telix. By combining our cyclotron leadership with Telix’s innovative approach and ARTMS technology, we are working to accelerate the availability of advanced diagnostic tools. This collaboration exemplifies our mission to protect, enhance, and save lives by making nuclear medicine more accessible worldwide and delivering meaningful impact for patients.”

Chad Watkins, General Manager Isotope Strategy at Telix added:
“Expanding our isotope production and manufacturing capabilities at RLS with IBA’s technology and the ARTMS QIS system is a critical step in improving patient outcomes. This investment in the RLS/Telix network will help ensure that clinicians have reliable, nationwide access to the precision tools they need to diagnose and treat cancer more effectively.”

Industry Partnerships Homepage